These discrepancies may stem from multiple factors: 1.Anatomical heterogeneity – HER-2’s prognostic impact appears context-dependent, with left-sided colon cancers showing different patterns from rectal tumors; 2.Molecular subtype variations – CMS2-enriched HER-2+ tumors may exhibit distinct biological behaviors; 3.Technical variability in HER-2 assessment methods across studies. The gene discussed is ERBB2; the disease is rectal neoplasm.